Lazard Speaks To Management // Reinterates Buy $19 PT. LINK
Fly On The Wall
Stock Market & Financial Investment News
June 19, 2013
13:01 EDT VNDA Vanda Pharmaceuticals's tasimelteon defended at Lazard Capital
Lazard spoke with management and said it has increased confidence in tasimelteon will gain FDA approval and in the outlook for Vanda. The firm would use weakness to aggressively to buy shares and reiterates its Buy rating.